Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Approval Strengthens Top Spot For AstraZeneca's Tagrisso

Gets EU Nod for Early-Stage NSCLC

Executive Summary

Competition may be on the horizon but Tagrisso's position as standard of care for EGFR-mutated NSCLC looks solid, not least after a thumbs-up in the EU for the adjuvant treatment of adults with early-stage disease.

You may also be interested in...



J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.

EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso

The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.

UK Pips EU To The Post With ‘Project Orbis’ Approval For Tagrisso

The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel